DuPont de Nemours, Inc. · NYSE:DD
DuPont de Nemours — DuPont — Proxy Contest (April 2015)
51 slides from DuPont de Nemours's proxy contest presentation, Apr 6, 2015
Slide 1: Spring 2015 DuPont Investor Presentation
AS FILED WITH THE SEC ON 04/06/2015 Spring 2015 DuPontDelivers.com 1
Slide 2: Regulation G and Forward-Looking Statements
REGULATION G The attached charts include company information that does not conform with generally accepted accounting principles (GAAP). Management believes the use of these non-GAAP measures are meaningful to investors because they provide insight with respect to operating results of the company an
Slide 3: A Global Science Company Delivering Higher Growth and Value
A Global Science Company Delivering Higher Growth and Value Company Overview • A science and innovation company delivering customized solutions to meet “Top 100 Global Innovator” for 4 consecutive years global challenges – Thomson Reuters (2014) • The next generation DuPont is positioned to captur
Slide 4: DuPont Is Delivering Superior Shareholder Value
DuPont Is Delivering Superior Shareholder Value 266% total shareholder return under current management, significantly outperforming proxy peers and the DuPont’s S&P 500 both before and after Trian’s investment(7,8) Leadership Has Ongoing business generated 6% compounded annual sales growth and a
Slide 5: Discussion Agenda
Discussion Agenda I. Proven Track Record of Success II. DuPont’s Strategy for Higher Growth and Higher Value III. Highly Qualified Board and Best-In-Class Corporate Governance IV. Trian’s High Risk Breakup Proposal V. Trian’s Proxy Fight VI. Concluding Remarks 5
Slide 6: DuPont's Strategy Is Working
DuPont’s Strategy Is Working “CEO Ellen Kullman deserves credit for delayering management, implementing cost cuts, and taking meaningful strategic actions that have upgraded the composition of DuPont’s portfolio” - Bank of America, September 18, 2014* Key Strategic Objectives Established in 2009...
Slide 7: Transformation Has Been Recognized By The Market
Transformation Has Been Recognized By The Market February 5, 2015: TSR Appoints world-class Directors, Ed Breen and 350% Jim Gallogly to the Board Total Shareholder Return (Through 12/31/2014)(1) January 28, 2014: 1-Year 3-Year 5-Year Mgmt Tenure Authorizes $5B share DuPont 17% 78% 160% 266% repurch
Slide 8: Executing DuPont's Strategic Portfolio Transformation
Executing DuPont’s Strategic Portfolio Transformation “Since Kullman took over as CEO of DuPont in 2009, she has stressed the need for constant reinvention and has pushed the 210-year-old company […] into faster-growing product areas” - McKinsey & Company, September 2012* Decisive Actions Taken To S
Slide 9: Strong Top Line and Margin Growth in Ongoing Businesses
Strong Top Line and Margin Growth in Ongoing Businesses 2008 – 2014 2008 – 2014 Total Segment Sales ($B)(9) Segment Adjusted Operating Margin(10) $28.5 16.9% $26.0 14.1% $20.1 9.5% 2008 2011 2014 2008 2011 2014 Continued Innovation and Operational Execution Have Driven Sales Growth and Margin Improv
Slide 10: Improved Profitability in DuPont's Ongoing Businesses
Improved Profitability in DuPont’s Ongoing Businesses 2014 Adjusted Percent of Improvement Segment EBITDA Margin(2) 2014 Sales(17) (2008 – 2014) Key Margin Drivers 2008 19.0% Robust innovation pipeline of higher value products Agriculture 40% +410bps 2014 23.1% and services enabling share gains; Adv
Slide 11: Resulting in Strong Earnings Growth
Resulting in Strong Earnings Growth 2008 – 2014 Adjusted Operating EPS $4.02 $4.01 $3.88 $3.77 $3.32 $0.84 $0.88 $1.99 $1.54 $3.17 $2.42 $1.43 $3.00 $1.91 $2.23 $1.32 $2.03 $1.89 $1.26 $1.10 $0.65 2008 2009 2010 2011 2012 2013 2014 Ongoing Business Performance Chemicals and Pharma The Success of DuP
Slide 12: Significant Return of Capital to Shareholders
Successful Execution of Our Strategy Has Enabled Significant Return of Capital to Shareholders Total Capital Returned to Shareholders(12) Strong Track Record of Capital Return $14B • Delivered 442 consecutive quarterly dividends since 1904 • Maintained dividend level through the Global Financial Cri
Slide 13: Discussion Agenda
Discussion Agenda I. Proven Track Record of Success II. DuPont’s Strategy for Higher Growth and Higher Value III. Highly Qualified Board and Best-In-Class Corporate Governance IV. Trian’s High Risk Breakup Proposal V. Trian’s Proxy Fight VI. Concluding Remarks 13
Slide 14: DuPont's Strategy to Deliver Higher Growth and Higher Value
DuPont’s Strategy to Deliver Higher Growth and Higher Value Build and Leverage World Leading Positions In Three Highly Attractive Strategic Focus Areas… Agriculture & Bio-Based Advanced Nutrition Industrials Materials Extend our leadership Develop world-leading Strengthen and grow our across the hig
Slide 15: Strong Execution Will Continue to Deliver Superior Growth
Strong Execution Will Continue to Deliver Superior Growth • Combine science and technology capabilities, global industry knowledge and market access to deliver value added Leverage solutions Innovation • Introduce next generation products and expand applications Platform to in core and adjacent mark
Slide 16: Three Highly Attractive Strategic Areas for Growth
DuPont is Focused on Three Highly Attractive Strategic Areas for Growth Agriculture & Nutrition Bio-Based Industrials Advanced Materials Portfolio / • Seeds and Traits • Enzymes • Advanced Polymers Core Offerings • Crop Protection Products • Biofuels • Protective Materials • Specialty Food Ingredien
Slide 17: Agriculture & Nutrition
Agriculture & Nutrition Deliver Innovative Solutions from Our World-Leading Pipeline To Grow 2-3x GDP Large and Growing Attractive Markets(19) Leading Competitive Position Core Markets Size ($B)* CAGR Specialty Food Leading Capabilities Along The Ag-To-Food Value Chain Ingredients Market • Global pr
Slide 18: Advanced Materials
Advanced Materials Leverage Application-Based Innovation To Grow >1.5x GDP Large and Growing Attractive Markets(19) Leading Competitive Position Core Markets CAGR • Broad portfolio of high • Value Chain and Regulatory performance materials and Influence Industrial 3-6% patented technologies Industri
Slide 19: Bio-Based Industrials
Bio-Based Industrials Develop World-Leading Industrial Biotechnology To Drive Rapid Market Expansion and Grow >3x GDP Large and Growing Attractive Markets(19) Leading Competitive Position ~$50B+ Bio-based Biofuels & Unparalleled commercial Rapidly expanding DuPont Polymers, Energy capability, in
Slide 20: DuPont Positioned To Lead Industrial Bio-Based Technology Revolution
DuPont Positioned To Lead Industrial Bio-Based Technology Revolution Bio-Based Industrials • Industry pioneer • Protein engineering • Hi-throughput screening • Customer access across • Metabolic engineering • Fermentation scale-up broad range of industries • Fermentation and • Application and formul
Slide 21: Strategy to Deliver Higher Growth and Higher Value
DuPont’s Strategy to Deliver Higher Growth and Higher Value Agriculture Bio-Based Advanced Focused, clear, and compelling & Nutrition Industrials Materials Centered on attractive markets Revenues ($B) Advanced Materials Bio-Based Industrials ~$40-45* Enabled by our strong competitive Agricultu
Slide 22: Discussion Agenda
Discussion Agenda I. Proven Track Record of Success II. DuPont’s Strategy for Higher Growth and Higher Value III. Highly Qualified Board and Best-In-Class Corporate Governance IV. Trian’s High Risk Breakup Proposal V. Trian’s Proxy Fight VI. Concluding Remarks 22
Slide 23: World-Class Board With The Right Mix of Skills and Experience
World-Class Board With The Right Mix of Skills and Experience Highly Qualified Directors Director Skills Evaluation Matrix • True Executive Experience Science / Growth Science and Industry International — 10 of 12 Board members are current or former CEOs, Technology Related Markets CFOs, or COOs of
Slide 24: Two New Highly-Qualified Directors Bring Fresh Perspectives
Two New Highly-Qualified Directors Bring Fresh Perspectives Edward Breen (59) James Gallogly (62) Lead Director Chairman & Former CEO Former President & COO Former Chairman of the Former EVP Former President & CEO Management Board & CEO Rescue of TYCO International Turnaround of LyondellBasell • 738
Slide 25: DuPont's Best-In-Class Board of Directors
DuPont’s Best-In-Class Board of Directors Ellen Kullman (Chair & CEO) Alexander Cutler (Lead Director) Lamberto Andreotti • 27 years of experience at DuPont • Chairman & CEO of Eaton • CEO and Chairman-elect of Bristol-Myers • Founded Industrial Biosciences and • Delivered 576% TSR vs. S&P 500’s 90%
Slide 26: Close Alignment of Pay and Performance
Close Alignment of Pay and Performance Majority of Pay is “At Risk” (2014) Strong Shareholder Support CEO Target Pay Other NEO Average Target Pay 97% 95% 94% 97% 11% 20% 89% 80% “At Risk” “At Risk” 2011 2012 2013 2014 = Performance-Based = Base Salary Say-on-Pay Vote Results (STIP + LTIP) Effective
Slide 27: Corporate Governance Best Practices
Corporate Governance Best Practices • 11 of 12 Directors are independent • 6 new Directors added since 2011 ensures fresh perspectives Independent • Average Board tenure of 5.8 years (below the S&P average of 8.4 years) Leadership and • Executive sessions held by independent directors at every board
Slide 28: Discussion Agenda
Discussion Agenda I. Proven Track Record of Success II. DuPont’s Strategy for Higher Growth and Higher Value III. Highly Qualified Board and Best-In-Class Corporate Governance IV. Trian’s High Risk Breakup Proposal V. Trian’s Concluding ProxyRemarks Fight VI. Concluding Remarks 28
Slide 29: DuPont Conducted a Comprehensive Evaluation of Trian's Proposals
DuPont Conducted a Comprehensive Evaluation of Trian’s Proposals Despite More Than 20 Meetings With Trian Has Criticized DuPont’s Lack of Engagement DuPont’s Lead Director / Senior Management “We were very frustrated by the lack of interaction after • More than half of the engagements involved our w
Slide 30: Trian's Breakup Plan Would Destroy Shareholder Value
Trian’s Plan to Breakup DuPont Would Result In Significant Destruction of Shareholder Value × Substantial Upfront Impact Estimated to be $4 billion(25) — Impact of significant one-time costs including debt breakage, separation charges, tax implications, and other potential additional one-time fundin
Slide 31: Trian's Plan to Add Debt Would Increase Risk
Trian’s Plan to Add Debt Would Increase Risk and Jeopardize DuPont’s Financial Flexibility × Trian’s proposal relies on financial engineering, introducing significant risk while decreasing DuPont’s ability to: — Fund growth R&D and capex — Pursue important strategic opportunities — React to and with
Slide 32: Independent Research Analysts Have Raised Concerns With Trian's Analysis
Independent Research Analysts Have Raised Significant Concerns With Trian’s Analysis “Value destruction from a complete split could be about $20B from lost working capital efficiencies, high taxes from asset sale gains, and additional overhead from splitting businesses, among other factors. We maint
Slide 33: Discussion Agenda
Discussion Agenda I. Proven Track Record of Success II. DuPont’s Strategy for Higher Growth and Higher Value III. Highly Qualified Board and Best-In-Class Corporate Governance IV. Trian’s High Risk Breakup Proposal V. Trian’s Proxy Fight VI. Concluding Remarks 33
Slide 34: Trian's Unconstructive Pattern of Engagement
Trian’s Unconstructive Pattern of Engagement 24-Jul: Trian presents 5-Dec: Trian’s 2nd 16-Sep: Trian submits 4-Feb: Trian rebuffs DuPont’s 11-Mar: Trian demands White Paper proposing Ultimatum: and publicly discloses settlement outreach and an immediate in-person a breakup of the (1) Accept Trian’s
Slide 35: Trian Seeks to Remove Strong Leaders With Critical Skills
Trian Seeks to Remove Strong Leaders With Critical Skills Alexander M. Cutler, Lead Director Robert A. Brown, Ph.D. Former Governance President Former Provost & Former President Chairman & CEO Committee Chair Professor of Chemical Engineering Committees: • Strong and highly engaged as DuPont’s Lead
Slide 36: Trian and Nelson Peltz Are Not Right For DuPont
Trian and Nelson Peltz Are Not Right For DuPont Not Qualified to Manage a “Does Trian Fit the Skills Needed for the Board? When we pull up Science Driven Business DD’s matrix of qualifications to be a Board member from its Corporate Governance link, it’s quite apparent that a well-balanced Previous
Slide 37: Trian's Nominees Offer No Incremental Value to DuPont's Board
Trian’s Nominees Offer No Incremental Value to DuPont’s Board Nelson Peltz Ed Garden (Trian Partner) (Trian Partner; Alternate Nominee) × Track record of failed board leadership role at the chemical company Chemtura (Garden) × Primary goal is to advance a break up proposal × Unproductive negotiation
Slide 38: Trian's Platform Based on Misrepresentations and Distorted Analyses
Trian’s Platform is Based on Misrepresentations and Distorted Analyses Trian’s Myths The Facts × Trian is responsible for all DuPont’s current Board and management team have a well-documented record of taking decisive action recent value creation at since 2009 and continue to execute on a transfor
Slide 39: Trian's Only Chemicals Board Representation Resulted in Bankruptcy
Trian’s Only Board Representation in the Chemicals Space Resulted in Bankruptcy and Total Loss of Shareholder Value Chemtura Total Shareholder Return: Trian’s Playbook Applied to a Science and Since Trian Involvement on Board(36) Chemicals Company Led to Bankruptcy Dec 18, 2007: announces Jun 26, 20
Slide 40: Market Commentators Are Skeptical of Trian's Plan
Market Commentators Are Skeptical of Trian’s Plan “On CNBC last week, Peltz was asked why he insists that he be the one to join DuPont’s board. Peltz’s response: He has industry experience…. If that experience is any guide, DuPont shareholders might want to keep Peltz as far away from their company’
Slide 41: Discussion Agenda
Discussion Agenda I. Proven Track Record of Success II. DuPont’s Strategy for Higher Growth and Higher Value III. Highly Qualified Board and Best-In-Class Corporate Governance IV. Trian’s High Risk Breakup Proposal V. Trian’s Proxy Fight VI. Concluding Remarks 41
Slide 42: DuPont is Delivering Superior Shareholder Value
DuPont is Delivering Superior Shareholder Value “Ellen Kullman has basically been an activist within DuPont to get that business to best-in-class operating metrics […] we celebrate Ellen’s moves to improve the portfolio and to de-complex the portfolio” - Ed Garden, Chief Investment Officer and Found
Slide 43: DuPont's Plan Has And Will Deliver Strong Results
DuPont’s Plan Has And Will Deliver Strong Results Vote FOR the DuPont Directors Driving This Value Creation DuPont has been outperforming the market and our peers in terms of total shareholder return since well before Trian’s investment(7,8) The underlying growth of our core businesses demonstra
Slide 44: Protect Your Investment: Vote For DuPont's Nominees
PROTECT YOUR INVESTMENT VOTE FOR DUPONT’S NOMINEES ON THE CARD 44
Slide 45: Additional Materials
Additional Materials 45
Slide 46: Performance Coatings Sale Was Highly Successful
Performance Coatings Sale Was Highly Successful Management Took Aggressive …Achieved a Strong …and Executed a Key Step in Action to Improve Performance… Sale Valuation… DuPont’s Strategic Transformation Perf. Coatings Operating 2012 EBITDA Continued portfolio re-alignment Income ($MM)(39) EBITDA D
Slide 47: Trian's Analysis of DuPont's Cost Structure Is Inaccurate and Misleading
Trian’s Analysis of DuPont’s Cost Structure Is Inaccurate and Misleading Trian Analysis Key Flaws In Trian’s Analysis ($mm) Trian Corrected Explanation Trian’s Subjective Estimate of 2011 Incorrect × To Calculate 2011 2012 • 5x operating income improvement 2009-2012 “Excess” Cost • DuPont owned and
Slide 48: Notes
Notes 1) Thomson Reuters Datastream; Total shareholder return is calculated as the appreciation or depreciation of a particular share, plus any dividends, over a given period, expressed as a percentage of the share’s value at the beginning of the period. Closing prices are adjusted for spin-offs, st
Slide 49: Notes (Cont'd)
Notes (Cont’d) 22) Director performance metrics from Thomson Reuters Datastream and public filings; Total shareholder return calculated from undisturbed date prior to assuming role through 12/31/2014, or until he/she no longer held the position, whichever was sooner. 23) From the 2009 rankings by Et
Slide 50: Reconciliation of Non-GAAP Measures (Unaudited)
Reconciliation of Non-GAAP Measures (Unaudited) (dollars in millions) RECONCILIATION OF SEGMENT PRE-TAX OPERATING INCOME (PTOI) TO ADJUSTED SEGMENT EBITDA Electronics & Nutrition & Safety & Performance Industrial Performance Total Year Ended December 31, 2014 Agriculture Communications Health Protec
Slide 51: Reconciliation of Non-GAAP Measures (Unaudited)
Reconciliation of Non-GAAP Measures (Unaudited) (dollars in millions, except per share) RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED) (dollars in millions, except per share) Year Year Year SEGMENT SALES 2014 2011 2008 Total Segment Sales (a) 35,011 34,087 26,499 Less: Performance Chemicals (b) 6,4